Saturday, 18 May, 2024
HomeCoronavirusInfection with original strain protects against severe COVID after infection by variant...

Infection with original strain protects against severe COVID after infection by variant — UCT

Emeritus Professor Jonny Myers, an occupational health and public health medicine specialist in the Centre for Environmental and Occupational Health Research at the department of public health and family medicine at University of Cape Town writes in Daily Maverick:

Looking at the data collated from Western Cape metro subdistricts during the two waves of the pandemic it is clear that Khayelitsha and Klipfontein subdistricts, where non-pharmaceutical interventions are difficult to implement, especially in the context of informal housing, have suffered a less severe second wave compared to their first. This contrasts strongly with the predominantly formal housing subdistricts which have suffered a more severe second wave.

The new daily case rate graph shows this quite clearly. Given that cases are unreliable indicators, the death rate graph shows the same thing, although a little less neatly.


If one counts the deaths under the curves a clearer picture emerges.


The table above shows the percentage increase or decrease in second wave cumulative deaths compared with first wave cumulative deaths. Both Khayelitsha and Klipfontein health subdistricts show decreases in second wave deaths compared with their first wave deaths.

On the other hand, the other subdistricts show increases in second wave deaths compared with their first wave deaths (Western, Eastern, Southern and Northern are predominantly formal housing areas while Mitchells Plain and Tygerberg subdistricts show more equivocal results in the table).

The fact that in the second wave, caused predominantly by the new variant, Khayelitsha and Klipfontein had fewer deaths than in the first waves caused by the original virus prototype, while the other subdistricts had more deaths in the second waves than in their first waves, provides evidence that natural infection with the original SARS2 strain does confer a level of effective protection against severe COVID disease leading to death caused by infection with the new variant.

We also know from the Novavax vaccine trial by Professor Shabir Madhi that there was a similar attack rate for the new variant in those triallists receiving placebos, irrespective of their having had antibodies to the original virus in the first wave prior to vaccination.

This means that immunity built up as a result of their original infection did not prevent reinfection with the new variant and mild COVID disease. However, Madhi’s subjects were too young and healthy to examine vaccine efficacy for severe COVID disease, specifically deaths.

The Western Cape data strongly suggest that natural immunity from infections with the original virus protects against severe disease/mortality.

We know that, as with natural infection by the original virus, the AstraZeneca vaccine produces both neutralising antibody as well as T-cell immunity responses, which protect against severe COVID and death. We can then infer from the Western Cape data that the AstraZeneca and other first-generation vaccines are likely to protect, perhaps mainly through T-cell cross-immunity, against severe disease and death from new variant infections.

While it is not yet clear what will be done with the 1.5m doses of South Africa’s AstraZeneca vaccines that will expire in April, it would be better to use these for voluntary participants in the relevant priority groups rather than letting them go to waste.


[link url=""]Full Daily Maverick report (Open access)[/link]

MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.